Cultured CD4T cells and primary human lymphocytes express hOATPs: Intracellular accumulation of saquinavir and lopinavir

British Journal of Pharmacology

Volumn 155, Issue 6, 2008, Pages 875-883

  Janneh, O ^a,b   Hartkoorn, R C ^b   Jones, E ^b   Owen, A ^b   Ward, S A ^c   Davey, R ^d   Back, D J ^b   Khoo, S H ^b  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Efflux; Estrone 3 sulphate; Influx; Lipophilicity; Lopinavir; Montelukast; Saquinavir

Indexed keywords

ESTRONE SULFATE; FUROSEMIDE; GLYCOPROTEIN P; LOPINAVIR; MONTELUKAST; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORT POLYPEPTIDE 3A1; ORGANIC ANION TRANSPORTER; SAQUINAVIR; TARIQUIDAR; UNCLASSIFIED DRUG; VERLUKAST;

ARTICLE; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL LINE; CULTURE MEDIUM; DRUG UPTAKE; HUMAN; HUMAN CELL; LIPOPHILICITY; LYMPHOCYTE CULTURE; NUCLEOTIDE SEQUENCE; PARTITION COEFFICIENT; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HIV PROTEASE INHIBITORS; HUMANS; LYMPHOCYTES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PYRIMIDINONES; SAQUINAVIR;

EID: 57349197111     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.320     Document Type: Article

References (33)

1. Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA, Burger DM (2003). Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 63: 741-753.
2. Agarwal S, Pal D, Mitra AK (2007). Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int J Pharm 339: 139-147.
3. Beck W, Mueller T, Tanzer L (1979). Altered surface membrane glycoproteins in vinka alkaloid-resistant human leukemic lymphoblasts. Cancer Res 39: 2070-2076.
4. Campbell SD, de Morais SM, Xu JJ (2004). Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact 150: 179-187.
5. Chapman EH, Kurec AS, Davey FR (1981). Cell volumes of normal and malignant mononuclear cells. J Clin Pathol 34: 1083-1090.
6. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR et al. (2000). Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28: 655-660.
7. Davey MW, Hargrave RW, Davey RA (1996). Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukaemia cells. Leuk Res 20: 657-664.
8. Davey RA, Longhurst TJ, Davey MW, Belov L, Harvie RM, Hancox D et al. (1995). Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line. Leuk Res 19: 275-282.
9. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD (2007). Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 35: 1853-1859.
10. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ et al. (2002). Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71: 11-20.
11. Ford J, Khoo SH, Back DJ (2004). The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother 54: 982-990.
12. Gerber JG, Acosta EP (2003). Therapeutic drug monitoring in the treatment of HIV-infection. J Clin Virol 27: 117-128.
13. Gibbs JE, Thomas SA (2002). The distribution of the anti-HIV drug, 2′3′-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors. J Neurochem 80: 392-404.
14. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH et al. (2002). Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16: 2295-2301.
15. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH (2001). P-glycoprotein limits oral availability, brain, and foetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 59: 806-813.
16. Janneh O, Jones E, Chandler B, Owen A, Khoo SH (2007). Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4T cells and primary human lymphocytes. J Antimicrob Chemother 60: 987-993.
17. Janneh O, Owen A, Chandler B, Hartkoorn RC, Hart CA, Bray PG et al. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 19: 2097-2102.
18. Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA et al. (2001). P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 15: 1353-1358.
19. Kim AE, Dintaman JM, Waddell DS, Silverman JA (1998). Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 286: 1439-1445.
20. Kim RB (2003). Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 33 (Suppl 2): 1-5.
21. Kim RB (2005). Transporters and drug discovery: why, when, and now. Mol Pharm 3: 26-32.
22. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F et al. (2001). Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120: 525-533.
23. la Porte CJL, Back DJ, Blaschke T, Boucher CAB, Flexner CV, Gerber JG et al. (2006). Updated guidelines to perform therapeutic drug monitoring for antiviral agents. Antivir Ther 3: 4-14.
24. Letschert K, Faulstich H, Keller D, Keppler D (2006). Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci 91: 140-149.
25. Meier PJ, Stieger B (2002). Bile salt transporters. Annu Rev Physiol 64: 635-661.
26. Owen A, Janneh O, Hartkoorn RC, Chandler B, Bray PG, Martin P et al. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. J Pharmacol Exp Ther 314: 1202-1209.
27. Roe M, Folkes A, Ashworth P, Brumwell J, Chima L, Hunjan S et al. (1999). Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett 9: 595-600.
28. Schiffer R, Neis M, Holler D, Rodriguez F, Geier A, Gartung C et al. (2003). Active influx transport is mediated by members of the organic anion transporting polypeptide family in human epidermal keratinocytes. J Invest Dermatol 120: 285-291.
29. Su Y, Zhang X, Sinko PJ (2004). Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm 1: 49-56.
30. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M et al. (2000). Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273: 251-260.
31. Tirona RG, Leake BF, Wolkoff AW, Kim RB (2003). Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304: 223-228.
32. Williams GC, Liu A, Knipp G, Sinko PJ (2002). Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother 46: 3456-3462.
33. Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ (2005). MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS 19: 1617-1625.